Regenerative Medical Technology (RMTG) Retained Earnings (2017 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Retained Earnings of -$76.2 million for Q1 2026, down 289.74% year-over-year from $40.2 million in Q1 2025, and down 287.76% quarter-over-quarter from $40.6 million in Q4 2025.
Regenerative Medical Technology (RMTG) Retained Earnings (2017 - 2026) Analysis & Trends
Regenerative Medical Technology's Retained Earnings history runs 10 years deep, the most recent figure standing at -$76.2 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 289.74% year-over-year to -$76.2 million; the TTM figure through Mar 2026 stood at -$76.2 million (down 289.74% YoY), while the FY2025 annual figure was $40.6 million, up 1.05% from the prior year.
- Retained Earnings for Q1 2026 stood at -$76.2 million, down from $40.6 million in the prior quarter.
- The five-year high for Retained Earnings was $43.9 million in Q3 2025, with the low at -$76.2 million in Q1 2026.
- The 5-year median for Retained Earnings is $40.2 million (2023), against an average of -$593988.3.
- The sharpest annual moves came in 2023 and 2026: Retained Earnings jumped 183.11% in 2023, then slumped 289.74% in 2026.
- Regenerative Medical Technology's Retained Earnings stood at -$52.2 million in 2022, then surged by 177.01% to $40.2 million in 2023, then gained by 0.0% to $40.2 million in 2024, then increased by 1.05% to $40.6 million in 2025, then sank by 287.76% to -$76.2 million in 2026.
- Business Quant data shows RMTG's Retained Earnings at -$76.2 million in Q1 2026, $40.6 million in Q4 2025, and $43.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Regenerative Medical Technology | 1.58 Mn | 515,228.12 | 1.77 Mn | -76.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -76.24 Mn |
| Dec 31, 2025 | 40.61 Mn |
| Sep 30, 2025 | 43.90 Mn |
| Jun 30, 2025 | -69.62 Mn |
| Mar 31, 2025 | 40.18 Mn |
| Dec 31, 2024 | 40.18 Mn |
| Sep 30, 2024 | 40.18 Mn |
| Jun 30, 2024 | 40.18 Mn |
| Mar 31, 2024 | -63.95 Mn |
| Dec 31, 2023 | 40.18 Mn |
| Sep 30, 2023 | 40.18 Mn |
| Jun 30, 2023 | -55.88 Mn |
| Mar 31, 2023 | 40.18 Mn |
| Dec 31, 2022 | -52.18 Mn |
| Sep 30, 2022 | 40.17 Mn |
| Jun 30, 2022 | -49.84 Mn |
| Mar 31, 2022 | -48.35 Mn |
| Dec 31, 2021 | 39.90 Mn |
| Sep 30, 2021 | 39.58 Mn |
| Jun 30, 2021 | 38.47 Mn |